Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF THE BOARD COMMITTEES; AND COMPLIANCE WITH RULE 3.10(2) AND 3.21 OF THE LISTING RULES

The Board hereby announces the following changes with effect from 10 February 2026:

Ms. Tam Mei Chu has been appointed as an independent non-executive Director and a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board.

The board (the "**Board**") of directors (the "**Director(s)**") of Zhong Ji Longevity Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces the following changes with effect from 10 February 2026.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Ms. Tam Mei Chu ("**Ms. Tam**") has been appointed as an independent non-executive Director with effect from 10 February 2026.

The biographical details of Ms. Tam are set out as follows:

Ms. Tam, aged 38, holds a Bachelor of Business Administration (Honours) in Accounting from the Hong Kong Metropolitan University (formerly known as the Open University of Hong Kong) in Hong Kong. She is a member of the Hong Kong Institute of Certified Public Accountants and a practicing certified public accountant in Hong Kong. She has extensive experience in auditing and company secretarial services. She serves as a company secretary of (i) China Energy Storage Technology Development Limited (stock code: 1143), a company listed on the main board (the "**Main Board**") of the Stock Exchange; (ii) Hong Kong Entertainment International Holdings Limited (stock code: 8291), a company listed on the GEM of the Stock Exchange; (iii) Ju Fu Tang Biotech Holdings Co., Ltd (formerly known as "**WMHW Holdings Limited**") (stock code: 8217), a company listed on the GEM of the Stock Exchange; (iv) China 33 Media Group Limited (stock code: 8087), a company listed on the GEM of the Stock Exchange; and (v) Aidigong Maternal & Child Health Limited, a company listed on the Main Board of the Stock Exchange (stock code: 286). She has served as an independent non-executive director of (i) Founder Holdings Limited (stock code: 418), a company listed on the Main Board of the Stock Exchange, since December 2025; (ii) Minerva Group Holding Limited (stock code: 397), a company listed on the Main Board of the Stock Exchange, since March 2022; and (iii) Link Holdings Limited (stock code: 8237), a company listed on the GEM of the Stock Exchange from May 2023 to January 2025.

Save as disclosed above, as at the date of this announcement, Ms. Tam has confirmed that she (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; and (iv) does not hold any other positions within the Company and other members of the Group.

Ms. Tam has entered into an appointment letter with the Company with an initial term of three years. Ms. Tam is subject to retirement by rotation and re-election (if applicable) at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. She is entitled to receive a director's fee of HK$20,000 per month, which is determined by the remuneration committee of the Company and the Board, and is subject to annual review with reference to the prevailing market conditions, her duties and responsibilities and the time she spent on the affairs of the Company.

Ms. Tam confirmed that she (i) met the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of his appointment.

Before Ms. Tam's appointment became effective, reference is made to the announcement of the Company dated 27 November 2025 (the "**Announcement**") in relation to, among others, the resignation of Mr. Lee See Barry as an independent non-executive Director with effect from 27 November 2025 (the "**Resignation**"). Following the Resignation, the Company does not have an independent non-executive Director who possesses appropriate professional qualifications or accounting or related financial management expertise (the "**Relevant Qualification**") as required under Rule 3.10 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and the Audit Committee does not have an independent non-executive Director with the Relevant Qualifications as required under Rule 3.21 of the Listing Rules. Following the appointment of Ms. Tam as an independent non-executive Director with effect from 10 February 2026, the Company has fully complied with Rule 3.10(2) and 3.21 of the Listing Rules, which stipulate that the Company and the Audit Committee must have at least one independent non-executive Director with appropriate professional qualifications or accounting or related financial management expertise.

On 9 February 2026, Ms. Tam had obtained legal advice from a firm of solicitors qualified to advise on Hong Kong law referred to in Rule 3.09D of the Listing Rules and had confirmed that she understood her obligations as a Director and the possible consequences of making a false declaration or giving false information to the Stock Exchange. As at the date of this announcement and save as disclosed above, Ms. Tam confirmed that there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders or the Stock Exchange, and there is no other

information that should be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules. The Board would like to take this opportunity to welcome Ms. Tam for joining the Board.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 10 February 2026

As at the date of this announcement, the Directors are:

Executive Directors
Mr. Yan Li
(Chairman and Chief Executive Officer)
Mr. Li Xiaoshuang

Non-executive Directors
Dr. He Yiwu
Mr. Lyu Changshang

Independent Non-executive Directors
Mr. Huang Jiang
Prof. Huang Cibo
Ms. Wang Huijuan
Ms. Tam Mei Chu

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.